Abstract
Recurrent head and neck squamous cell carcinoma (HNSCC) remains a difficult cancer to treat. Here, we describe a patient with HNSCC who had complete response to methotrexate (MTX) after progressing on multiple cytotoxic agents, cetuximab, and AMG-479 (monoclonal antibody against insulin-like growth factor-1 receptor [IGF-1R]). The clinical information was collected by a retrospective medical record review under an Institutional Review Board-approved protocol. From 4 tumors and 2 normal mucosal epithelia, global gene expression, and IGF-1R and dihydrofolate reductase (DHFR) protein levels were determined. Effective target inhibition in the tumor was confirmed by the decreased protein levels of total and phospho-IGF-1R after treatment with AMG-479. Decreased level of DHFR and conversion of a gene expression profile associated with cetuximab-resistance to cetuximab-sensitivity were also observed. This suggests that the combination of AMG-479 and MTX or cetuximab may be a promising therapeutic approach in refractory HNSCC.
References
Jun 13, 1998·Journal of the National Cancer Institute·J Rubin GrandisD J Tweardy
Mar 15, 2001·The New England Journal of Medicine·D J SlamonL Norton
Apr 5, 2001·The New England Journal of Medicine·B J DrukerM Talpaz
May 16, 2002·The Journal of Biological Chemistry·Andrew P GilmoreCharles H Streuli
May 1, 2004·Science·J Guillermo PaezMatthew Meyerson
Jul 24, 2004·Endocrinology·Ami KuribayashiMasahiko Miura
Mar 10, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David B SolitFrank M Sirotnak
Aug 17, 2006·Cancer Research·Christine H ChungWendell G Yarbrough
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine H ChungFred R Hirsch
Sep 26, 2006·Cancer Letters·Mark G SlomianySteven A Rosenzweig
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce J GiantonioUNKNOWN Eastern Cooperative Oncology Group Study E3200
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan B VermorkenJosé Baselga
Jul 20, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christopher J BarnesRakesh Kumar
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wu ZhangHeinz-Josef Lenz
Sep 18, 2007·Journal of Molecular Biology·Jordan P VolpatoJoelle N Pelletier
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Apr 16, 2009·Molecular Cancer Therapeutics·Pedro J BeltranFrank J Calzone
Citations
Aug 25, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·He WangVikram Deshpande
Feb 1, 2013·PloS One·Giannis MountziosGeorge Fountzilas
Jul 3, 2013·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Kirsten H LimesandAndrew Fribley
Jun 8, 2014·Bioinformatics·Hilary S ParkerElana J Fertig
Jul 4, 2013·The Oncologist·Carolien BoeckxFilip Lardon
May 20, 2015·Genes & Diseases·Sahitya K DenduluriHue H Luu
May 13, 2014·Targeted Oncology·Josep TaberneroJosé Baselga
Jul 1, 2016·Pediatric Blood & Cancer·Peter M AndersonDavid Mauro
Oct 18, 2011·Expert Opinion on Drug Metabolism & Toxicology·Joshua G YorgasonFederico Kalinec
Apr 5, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amanda PsyrriArlene A Forastiere
May 25, 2018·Cancer Research·Brandon LeonardNeil E Bhola
Mar 16, 2021·Frontiers in Oncology·Sandra Ortiz-CuaranPierre Saintigny